NCT04839380View on ClinicalTrials.gov

The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL

Enrollment

49

Participants

Timeline

Start Date

October 12, 2021

Primary Completion Date

November 18, 2022

Study Completion Date

November 18, 2022

Conditions

Atopic Dermatitis

Interventions

DRUG

ruxolitinib cream

ruxolitinib cream 1.5% will be applied twice daily as a thin film

Trial Locations (2)

H2K 4L5

Innovaderm Research Inc., Montreal

H2K 4LS

Innovoderm Research, Montreal

Sponsors

Lead Sponsor

Incyte Corporation

All Listed Sponsors

lead

Incyte Corporation

INDUSTRY